Monday, 31 October 2011 -- Cobra Biologics, the international manufacturer of biopharmaceuticals is pleased to announce as part of its strategy to expand its service offering the acquisition of Unitech Pharma Group and its bio-production facility in Matfors near Sundsvall, Sweden.
Under the terms of the agreement, Cobra Biologics will acquire 100% of the shareholding in Unitech Pharma Group, which provides a 600L clinical and commercial microbial GMP production capacity, commercial aseptic fill/finish and lyophilisation capability.
Peter Coleman, CEO of Cobra commented: “I am delighted to announce this acquisition as it significantly enhances Cobra’s service offering to our customers. The facility in Matfors will bring over 20 years of bio-production experience to Cobra, with their offering perfectly complimenting Cobra’s existing expertise and capacity. This is the first step as a newly independent business in our intention to expand and grow our business, to provide the best possible service for our customers.”
Cobra’s comprehensive service offering now includes cell line development, analytical and process development, GMP production, fill/finish, product release for Phase I, II, III clinical trials and in-market supply.
For more information about Cobra Biologics, please contact Peter Coleman, CEO, on +44 (0)1782 714181 or email peter.coleman@cobrabio.com.
For media enquiries, please contact Tristan Jervis or Alex Heeley on +44 (0)207 861 3019 or email: t.jervis@defacto.com
